Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Otsuka’s Q1 Pharma Sales Climb 20.3% Buoyed by Global Products
May 15, 2023
- Takeda Logs Record Sales, Breaks 4 Trillion Yen Mark in FY2022
May 12, 2023
- Astellas Loses Appeal Bid in Lexiscan Patent Infringement; Ruling Finalized
May 12, 2023
- Oral Radicava Approved in Switzerland: Mitsubishi Tanabe
May 12, 2023
- Rexulti Snags US Approval for Alzheimer’s Agitation: Otsuka/Lundbeck
May 12, 2023
- Xocova’s Uptake in Japan in Line with Expectations: Shionogi CEO
May 11, 2023
- Kyowa Kirin Axes Flagship Kidney Disease Drug Candidate
May 11, 2023
- Kyowa Kirin Cuts Net Profit Forecast after Kidney Disease Drug Jettisoned
May 11, 2023
- Shionogi Hits Record High Earnings on Xocova Boon in FY2022
May 11, 2023
- Opdivo-Yervoy Shows Similar Mortality Rates in Registration Trial and RWD: Ono
May 11, 2023
- Opdivo’s Japan Patent to Expire in 2031, Ono to Cover LOE with New Launches: Chief
May 11, 2023
- Ono Notches Two-Digit Growth in FY2022; Opdivo en Route to 150 Billion Yen Mark
May 11, 2023
- Japan Ethical Drug Sales Surge 3.9% in March: Crecon
May 11, 2023
- Roche’s Diagnostic Gets Japan Coverage to Identify HER2 Low Breast Cancer Patients Eligible for Enhertu
May 10, 2023
- Trulicity Shipment Control Continues, Lilly Calls for Use of Novo Drugs
May 10, 2023
- Eisai Cuts FY2022 Earnings Forecast on FX, Subpar Mainstay Results
May 10, 2023
- Opdivo Best-Selling Med in Japan for 16 Months Straight: Encise
May 10, 2023
- PeptiDream Unit Seeks Label Expansion for PET Diagnostic Amyvid
May 9, 2023
- Over 40% of Japan Drug Makers Allow Side Jobs, MSD Has Largest 188 Staffers Tapping Option: Poll
May 9, 2023
- Eisai, BlissBio to Codevelop ADC Using Eribulin
May 9, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…